Specialised Therapeutics to distribute European oncology drug
Specialised Therapeutics Australia (STA) has formed an exclusive licence and commercialisation agreement with European pharmaceutical partner company PharmaMar to market and distribute the oncology drug APLIDIN (plitidepsin) in Australia and New Zealand.
Obtained from the colonial sea squirt Aplidium albicans, APLIDIN is currently in development for the treatment of multiple myeloma and a type of T cell lymphoma. PharmaMar announced in June that patient recruitment of an international pivotal Phase 3 trial for the drug candidate in refractory/relapsed multiple myeloma had been successfully completed.
Under the terms of the new agreement, PharmaMar will receive an upfront payment, royalties and additional remunerations from STA for regulatory and sales milestones achieved by APLIDIN. PharmaMar will retain production rights and will supply the finished product to STA for exclusive commercial use in Australia and New Zealand.
“This drug is a welcome addition to STA’s expanding oncology portfolio and we look forward to making this treatment option available to patients in Australia and New Zealand, pending the release of pivotal Phase 3 data confirming its efficacy,” said STA CEO Carlo Montagner.
“We applaud PharmaMar’s commitment in developing this important therapy and are delighted to collaborate with a partner of this calibre.”
Softer tumours fuel spread of triple-negative breast cancer
A metabolic 'survival switch' controlled by the stiffness of triple-negative breast...
Maternal protein intake affects offspring's facial features
New study findings emphasise the importance of maintaining a well-balanced diet during pregnancy,...
Gene discovery offers hope for new kidney disease treatments
Researchers have identified a gene that plays a crucial role in regulating energy supply to cells...
